PharmAla Biotech Inc. is a Canadian biotechnology company focused on the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds. The company aims to support the scientific research community and facilitate commercial use in select jurisdictions by ensuring a steady supply of clinical-grade Active Pharmaceutical Ingredients (APIs). PharmAla is dedicated to advancing the medicinal use of MDMA, which is believed to have clinical potential for treating various disorders. The company is also engaged in the development of Novel Chemical Entities (NCEs) based on the MDXX class of molecules, with a focus on enhancing their safety profiles to broaden their therapeutic applications.

To achieve its goals, PharmAla collaborates with established laboratories across Canada to create innovative processes for the production of LaNeo™ MDMA and other MDXX substances, adhering to the highest standards of compliance and regulatory rigor. The company is actively involved in preclinical research aimed at improving the safety of MDMA and its analogs. PharmAla distinguishes itself as a "regulatory-first" organization, prioritizing the establishment of trust with regulators to facilitate drug approval pathways. Additionally, the company is developing novel formulation methods and delivery pathways to ensure that its products can be safely administered by researchers and clinicians, thereby addressing the current global shortage of MDMA for critical research purposes.

Canada

PharmAla Biotech Inc. is a Canadian Biotechnology company dedicated to the research, development, manufacture and sales of MDMA in service to the clinical research community.

PharmAla Biotech Inc.

Company Details